206
Views
11
CrossRef citations to date
0
Altmetric
Review

Interferon regulatory factor-5-regulated pathways as a target for colorectal cancer therapeutics

&
Pages 775-784 | Published online: 10 Jan 2014

References

  • Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J. Clin.54, 8–29 (2004).
  • McWilliams RA, Erlichman C. Novel therapeutics in colorectal cancer. Dis. Colon Rectum48, 1632–1650 (2005).
  • Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med.343, 905–914 (2000).
  • Graeven U, Andre N, Schmiegel W. Colorectal cancer: current treatment options. Z. Gastroenterol.42, 1399–1407 (2004).
  • Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet355, 1041–1047 (2000).
  • Awada A, Mano M, Hendlisz A, Piccart M. New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective. Expert Rev. Anticancer Ther.4, 53–60 (2004).
  • Miyamoto M, Fujita T, Kimura Y et al. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-β gene regulatory elements. Cell54, 903–913 (1988).
  • Nguyen H, Hiscott J, Pitha PM. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev.8, 293–312 (1997).
  • Mamane Y, Heylbroeck C, Genin P et al. Interferon regulatory factors: the next generation. Gene237, 1–14 (1999).
  • Harada H, Taniguchi T, Tanaka N. The role of interferon regulatory factors in the interferon system and cell growth control. Biochimie80, 641–650 (1998).
  • Barnes BJ, Lubyova B, Pitha PM. On the role of IRF in host defense. J. Interferon Cytokine Res.22, 59–71 (2002).
  • Tanaka N, Ishihara M, Lamphier MS et al. Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature382, 816–818 (1996).
  • Tanaka N, Ishihara M, Kitagawa M et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell77, 829–839 (1994).
  • Tamura T, Ishihara M, Lamphier MS et al. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature376, 596–599 (1995).
  • Pamment J, Ramsey E, Kelleher M, Dornan D, Ball KL. Regulation of the IRF-1 tumor modifier during the response to genotoxic stress involves an ATM-dependent signaling pathway. Oncogene21, 7776–7785 (2002).
  • Mori T, Anazawa Y, Iiizumi M, Fukuda S, Nakamura Y, Arakawa H. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene21, 2914–2918 (2002).
  • Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res.63, 6424–6431 (2003).
  • Hu G, Marcl ME, Barnes BJ. Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. Cancer Res.65, 7403–7412 (2005).
  • Tanaka N, Kawakami T, Taniguchi T. Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system. Mol. Cell Biol.13, 4531–4538 (1993).
  • Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science264, 1415–1421 (1994).
  • Driggers PH, Ennist DL, Gleason SL et al. An interferon γ-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc. Natl Acad. Sci. USA87, 3743–3747 (1990).
  • Goodbourn S, Zinn K, Maniatis T. Human β-interferon gene expression is regulated by an inducible enhancer element. Cell41, 509–520 (1985).
  • Goodbourn S, Maniatis T. Overlapping positive and negative regulatory domains of the human β-interferon gene. Proc. Natl Acad. Sci. USA85, 1447–1451 (1988).
  • Fujii Y, Shimizu T, Kusumoto M, Kyogoku Y, Taniguchi T, Hakoshima T. Crystal structure of an IRF-DNA complex reveals novel DNA recognition and cooperative binding to a tandem repeat of core sequences. EMBO J.18, 5028–5041 (1999).
  • Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol.19, 623–655 (2001).
  • Barnes BJ, Kellum MJ, Field AE, Pitha PM. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol. Cell. Biol.22, 5721–5740 (2002).
  • Yoneyama M, Suhara W, Fujita T. Control of IRF-3 activation by phosphorylation. J. Interferon Cytokine Res.22, 73–76 (2002).
  • Reich NC. Nuclear/cytoplasmic localization of IRFs in response to viral infection or interferon stimulation. J. Interferon Cytokine Res.22, 103–109 (2002).
  • Watanabe N, Sakakibara J, Hovanessein AG, Taniguchi T, Fujita T. Activation of IFN-β element by IRF-1 requires a posttranslational event in addition to IRF-1 synthesis. Nucleic Acids Res.19, 4421–4428 (1991).
  • Au WC, Moore PA, LaFleur DW, Tombal B, Pitha PM. Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes. J. Biol. Chem.273, 29210–29217 (1998).
  • Lin R, Heylbroeck C, Pitha PM, Hiscott J. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol. Cell. Biol.18, 2986–2996 (1998).
  • Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon αgenes. J. Biol. Chem.276, 23382–23390 (2001).
  • Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J.17, 1087–1095 (1998).
  • Caillaud A, Prakash A, Smith E et al. Acetylation of interferon regulatory factor-7 by p300/CREB-binding protein (CBP)-associated factor (PCAF) impairs its DNA binding. J. Biol. Chem.277, 49417–49421 (2002).
  • Iwamura T, Yoneyama M, Yamagachi K et al. Induction of IRF-3/-7 kinase and NF-κB in response to double-stranded RNA and virus infection: common and unique pathways. Genes Cells 6, 375–388 (2001).
  • Au WC, Pitha PM. Recruitment of multiple interferon regulatory factors and histone acetyltransferase to the transcriptionally active interferon a promoters. J. Biol. Chem.276, 41629–41637 (2001).
  • Izaguirre A, Barnes BJ, Amrute S et al. Comparative analysis of IRF and IFN-α expression in human plasmacytoid and monocyte-derived dendritic cells. J. Leukoc. Biol.74, 1125–1138 (2003).
  • Barnes BJ, Field AE, Pitha PM. Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes. J. Biol. Chem.278, 16630–16641 (2003).
  • Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, Pitha PM. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J. Biol. Chem.279, 45194–45207 (2004).
  • Mancl ME, Hu G, Sangster-Guity N et al. Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. J. Biol. Chem.280, 21078–21090 (2005).
  • Schoenemeyer A, Barnes BJ, Mancl ME et al. The interferon regulatory factor, IRF-5, is a central mediator of Toll-like receptor 7 signaling. J. Biol. Chem.280, 17005–17012 (2005).
  • Marie I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-α genes by positive feedback through interferon regulatory factor-7. EMBO J.17, 6660–6669 (1998).
  • Juang YT, Lowther W, Kellum M et al. Primary activation of interferon A and interferon B gene transcription by interferon regulatory factor 3. Proc. Natl Acad. Sci. USA95, 9837–9842 (1998).
  • Fitzgerald KA, Rowe DC, Barnes BJ et al. LPS-TLR4 signaling to IRF-3/7 and Nf-κB involves the Toll adapters TRAM and TRIF. J. Exp. Med.198, 1043–1055 (2003).
  • Morin P, Braganca J, Bandu MT et al. Preferential binding sites for interferon regulatory factors 3 and 7 involved in interferon-A gene transcription. J. Mol. Biol.316, 1009–1022 (2002).
  • Takaoka A, Yanai H, Kondo S et al. Integral role of IRF-5 in the gene induction programme activated by toll-like receptors. Nature434, 243–249 (2005).
  • Hayashida S, Yamasaki K, Asada Y, Soeda E, Niikawa N, Kishino T. Construction of a physical and transcript map flanking the imprinted MEST/PEG1 region at 7q32. Genomics66, 221–225 (2000).
  • Oscier DG, Gardiner A, Mould S. Structural abnormalities of chromosome 7q in chronic lymphoproliferative disorders. Cancer Genet. Cytogenetics92, 24–27 (1996).
  • Mertens F, Johansson B, Hoglund M, Mitelman F. Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res.57, 2765–2780 (1997).
  • Philips AV, Cooper TA. RNA processing and human disease. Cell. Mol. Life Sci.57, 235–249 (2000).
  • Nissim-Rafinia M, Kerem B. Splicing regulation as a potential genetic modifier. Trends Genet.18, 123–127 (2002).
  • Bunz F, Dutriaux A, Lengauer C et al.Science282, 1497–1501 (1998).
  • Ravi R, Bedi A. Potential mechanisms to circumvent blocks in apoptosis in lymphomas. Curr. Opin. Oncol.14, 490–503 (2002).
  • Yang J, Yu Y, Hamrick HE, Duerksen-Hughes PJ. ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. Carcinogenesis24, 1571–1580 (2003).
  • Yaffe MB, Leparc GG, Lai J, Obata T, Volinia S, Cantley LC. A motif-based profile scanning approach for genome-wide prediction of signaling pathways. Nat. Biotechnol.19, 348–353 (2001).
  • Hoppe BS, Jensen RB, Kirchgessner CU. Complementation of the radiosensitive M059J cell line. Radiat. Res.153, 125–130 (2000).
  • Sinicrope FA, Penington RC, Tang XM. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14–1, in human colon cancer cells. Clin. Cancer Res.10, 8284–8292 (2004).
  • Gura T. How TRAIL kills cancer cells, but not normal cells. Science277, 768 (1997).
  • Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res.59, 6153–6158 (1999).
  • Kelley SK, Harris LA, Xie D et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther.299, 31–38 (2001).
  • Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients’ colon tumors grown in SCID mice. Cancer Res.62, 5800–5806 (2002).
  • Strater J, Walczak H, Pufrop T et al. TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infection. Gastroenterol.122, 659–666 (2002).
  • Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science281, 1305–1308 (1998).
  • Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell102, 1–4 (2000).
  • van Geelen CM, de Vries EG, Le TK, van Weeghel RP, de Jong S. Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. Br. J. Cancer.89, 363–373 (2003).
  • Ravi R, Jain AJ, Schulick RD et al. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res.64, 9105–9114 (2004).
  • Nagane M, Huang HJ, Cavanee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis6, 191–197 (2001).
  • LeBlanc H, Lawrence D, Varfolomeev E et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med.8, 274–281 (2002).
  • Arizono Y, Yoshikawa H, Naganuma H, Hamada Y, Nakajima Y, Tasaka K. A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents. Br. J. Cancer88, 298–306 (2003).
  • Langaas V, Shahzidi S, Johnsen JI, Smedsrod B, Sveinbjornsson B. Interferon-γ modulates TRAIL-mediated apoptosis in human colon carcinoma cells. Anticancer Res.21, 3733–3738 (2001).
  • Green JE, Hudson T. The promise of genetically engineered mice for cancer prevention studies. Nat. Rev. Cancer5, 184–198 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.